Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Tralokinumab in Adult Subjects With Moderate-to-Severe Atopic Dermatitis

NCT02347176 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT02347176
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02347176 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Tralokinumab in Adult Subjects With Moderate-to-Severe Atopic Dermatitis
Lead sponsor
MedImmune LLC
Phase
Phase 2
Overall status
Completed
Start date
January 23, 2015
Completion date
February 5, 2016
Enrollment
204 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis